Pyng Medical Corp. Announces Election of Directors and Officers at 2010 Annual General Meeting and Issuance of Stock Options to a Director

VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 10, 2010) - Pyng Medical Corp. (the “Company”) (TSX VENTURE: PYT) announced today that at the Annual General Meeting (“AGM”) of the shareholders held on March 9, 2010, the following persons were elected as directors: Robert (“Bob”) DiSilvio, Kevin O’Neill, Michael Jacobs, R.J. (“Bud”) Evans, Al Moloff and Edward A. (Ted) Bence.

At a Board Meeting held immediately following the AGM on March 9, 2010, Bob DiSilvio was appointed as President & Chief Executive Officer of the Company and George Dorin, CA was appointed as Chief Financial Officer and Corporate Secretary. The Company’s Audit and Finance Committee, and Compensation Committee were also reconstituted for the ensuing year. The Company’s Stock Option Plan dated March 18, 2005, as amended March 5, 2008, was also reapproved until the next AGM, subject to filing with the TSXV.

The Company also announced today that it issued 150,000 common share stock options to a Director on March 10, 2010 (the “Effective Date”). The options have a five year term and an issue price of $0.20 per share. 1/3 of the total number of options granted will vest six months after the Effective Date, a further 1/3 of the total number of options granted will vest twelve months after the Effective Date, and the remaining 1/3 of the total number of options granted will vest eighteen months after the Effective Date.

On behalf of the Board of Directors of Pyng Medical Corp.

Kevin O’Neill, Director

Pyng Medical Corp.

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Creators of the FAST1® Intraosseous Infusion System, Pyng’s expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide. Pyng has received the exclusive 2008 Medical Device Company of the Year Award from Life Sciences British Columbia for its sustained achievements in commercializing the Company’s proprietary FAST1®, the only medical device able to provide rapid sternal access for administering drugs and fluids to the heart in seconds. The Company was also selected in the “2007 TSX Venture 50" Top 10 companies in Life Sciences based on solid financial metrics for the year ending December 31, 2006.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management’s expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company’s strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like “expects”, “anticipates”, “plans”, “intends”, “projects”, “indicates”, and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.